<DOC>
	<DOCNO>NCT00513578</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill cancer cell . Colony-stimulating factor , GM-CSF , increase number white blood cell platelets find bone marrow peripheral blood . Giving vaccine therapy together GM-CSF may kill cancer cell . PURPOSE : This phase II trial study well give vaccine therapy together GM-CSF work treat patient low-risk intermediate-risk myelodysplastic syndrome .</brief_summary>
	<brief_title>Vaccine Therapy GM-CSF Treating Patients With Low-Risk Intermediate-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine immunologic response , use PR1-HLA-A2 tetramer assay , 4 subcutaneous injection PR1 leukemia peptide vaccine formulate incomplete Freund 's adjuvant ( IFA ) follow sargramostim ( GM-CSF ) patient low- intermediate-1-risk myelodysplastic syndrome . Secondary - To determine non-immunologic responder 4 subcutaneous injection PR1 leukemia peptide vaccine formulate IFA follow GM-CSF convert immunologic responder administer 4 additional dos treatment . - To determine clinical response 4 8 subcutaneous injection vaccine . OUTLINE : This multicenter study . Patients receive proteinase PR1 leukemia peptide vaccine ( TVC-PR1 ) conjugate incomplete Freund 's adjuvant administer subcutaneously sargramostim ( GM-CSF ) . Patients receive series four vaccination 3-week interval . Non-immunologic responder 4 dos vaccine eligible receive 4 additional dos TVC-PR1 vaccine dose dose interval . Patients mount immunologic response 4 dos receive additional dos TVC-PR1 vaccine . After completion study therapy , patient follow monthly 6 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Diagnosis myelodysplastic syndrome ( MDS ) must meet following criterion : FAB class refractory anemia ( RA ) , RA excess blast ( RAEB ) , RA ring sideroblast ( RARS ) WHO Classification RA , RARS , refractory cytopenia multilineage dysplasia ( RCMD ) , RCMD ring sideroblast , RAEB1 Less 20 % blast marrow aspirate IPSS risk group intermediate1 OR transfusion dependent lowrisk Patients de novo therapyrelated MDS eligible HLAA2 positive one allele Exclusion criterion : RAEB transformation RAEB2 Chloroma Marrow blast aspirate ≥ 20 % Blood blast &gt; 1 % Inaspirable bone marrow History current myelosclerosis occupy &gt; 30 % marrow space History acute myeloid leukemia Other cause cytopenia relate MDS ( i.e. , gastrointestinal blood loss ) PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 0 1 Women childbearing potential must negative serum pregnancy test within 30 day start study drug Male female childbearing potential must agree use adequate contraceptive method Serum bilirubin &lt; 2 mg/mL Creatinine ≤ 1.5 mg/mL ALT &lt; 2 time upper normal limit Antineutrophil cytoplasmic antibody ( cANCA ) negative Exclusion criterion : Pregnant lactate Iron absence marrow examination transferrin saturation &lt; 20 % serum ferritin &lt; 50ng/mL B12 deficiency Folate deficiency History immunerelated hematological disorder ( i.e. , idiopathic thrombocytopenic purpura , autoimmune hemolytic anemia ) Life expectancy severely limited disease MDS Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease ≥ 5 year Known allergy incomplete Freund 's adjuvant Hypercalcemia Progressive viral bacterial infection All infection must resolve patient remain afebrile seven day without antibiotic Cardiac disease symptomatic nature cardiac ejection fraction &lt; 40 % History Wegener granulomatosis vasculitis Symptomatic pulmonary disease FEV_1 , FVC , DLCO ≤ 50 % predict History HIV positivity AIDS Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form place subject unacceptable risk he/she participate study confounds ability interpret data PRIOR CONCURRENT THERAPY : Exclusion criterion : Has receive specific therapy MDS within past 4 week Prior allogeneic syngeneic transplant Prior solid organ transplant Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 10 mg/day prednisone ) within 30 day first day study drug treatment Topical inhale corticosteroid permit Experimental therapy , cyclosporine , antithymocyte globulin , tacrolimus within 3 month study entry Treatment androgenic hormone , danazol , colonystimulating factor , erythropoietin , thalidomide , arsenic trioxide agent use treat MDS within four week first day study treatment Prior vaccine therapy MDS Prohibited medication study , include follow : Systemic steroid except require transfusion reaction Chemotherapy investigational drug Sargramostim ( GMCSF ) ( except part study regimen ) Filgrastim ( GCSF ) Interleukin11</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>